Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MMP12 | P39900 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 2/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | XDH | P47989 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12438641 | 0.77 | POLB (0.38) | PARP1ALDH1A1POLBADORA3HSP90AA1 | |
| SCHEMBL13594653 | 0.74 | ADRB2 (0.52) | PARP1ADRB2ALDH1A1SMN1; SMN2ADORA3 | |
| SCHEMBL15834705 | 0.74 | LMNA (0.44) | PARP1ALDH1A1POLBTDP1MMP12 | |
| SCHEMBL11204397 | 0.73 | MAPT (0.44) | PARP1ADORA3MMP12MAPTPRKCI | |
| SCHEMBL14648514 | 0.71 | ADRB2 (0.41) | PARP1ADRB2ALDH1A1ADORA3HTT | |
| SCHEMBL30945080 | 0.70 | ADRA2A (0.41) | ALDH1A1POLBMMP12MAPTHSD17B10 | |
| SCHEMBL38687 | 0.70 | ADRA2A (0.41) | ALDH1A1POLBMMP12MAPTHSD17B10 | |
| SCHEMBL1374558 | 0.70 | PRKCI (0.44) | PARP1ALDH1A1SMN1; SMN2TDP1MMP12 | |
| SCHEMBL11203532 | 0.69 | MAPT (0.44) | PARP1ADRB2ALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL23486023 | 0.69 | ADRB2 (0.39) | PARP1ADRB2ALDH1A1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2532665-B1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | XUANZHU PHARMA CO LTD (CN) | 2016-09-07 | — | — | EP | disclosed |
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD. (CN) | 2016-06-23 | — | — | US | disclosed |
| US-9315513-B2 | Benzimidazole derivatives and their pharmaceutical compositions and uses | Xuanzhu Pharma Co., Ltd. (CN) | 2016-04-19 | — | — | US | disclosed |
| EP-2532665-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Xuanzhu Pharma Co., Ltd. (CN) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095057-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | 山东轩竹医药科技有限公司 (CN) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176892-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS AND USES | F12, HRH2, H1-3 | PARP1 1226/4885ADRB2 747/4885ALDH1A1 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.